Jill Marie Broadfoot - Jan 5, 2024 Form 4 Insider Report for aTYR PHARMA INC (LIFE)

Role
Chief Financial Officer
Signature
/s/ Nancy E. Denyes, attorney-in-fact
Stock symbol
LIFE
Transactions as of
Jan 5, 2024
Transactions value $
$0
Form type
4
Date filed
1/9/2024, 07:33 PM
Previous filing
Dec 13, 2023
Next filing
Feb 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LIFE Common Stock 18.7K Jan 5, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIFE Employee Stock Option (right to buy) Award $0 +150K $0.00 150K Jan 5, 2024 Common Stock 150K $1.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,025 shares acquired on May 15, 2023 and 2,176 shares acquired on November 15, 2023 under the Company's 2015 Employee Purchase Plan.
F2 The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning February 5, 2024, such that this option will be fully exercisable on January 5, 2028. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.